Medical Industry News | Family Medicine

Editor's Choice

Making good decisions requires that physicians have reliable and practical data. Comparative effectiveness reviews and objective findings on different medical interventions and strategies, as provided by the Agency for Healthcare Research and Quality in its Effective Health Care Program, can help physicians make the most informed choices among treatment options.

LATEST ARTICLES

Drug abuse, counterfeits, and critical shortages illustrate need for secure drug supplies

The United States is caught in an epidemic of prescription drug overuse and abuse, and efforts to counter such activity are affecting drug distribution, prescribing, and oversight. Just as troubling is the appearance of counterfeit versions of critical drugs, and continued shortages of vital medications have generated interest in new approaches to ensure that the drug supply chain can reliably deliver safe and effective therapies.

Ingenol mebutate gel (Picato): A topical gel for the treatment of actinic keratosis

New molecular entity: FDA approved Ingenol mebutate gel, a topical gel for the treatment of acitinic keratosis

Diabetes-induced peripheral neuropathy: A treatment review

A review of treatments for diabetes-induced peripheral neruopathy

Glucarpidase (Voraxaze): for the intravenous injection to treat toxic levels of methotrexate due to kidney failure

New molecular entity: FDA approved Glucarpidase, an intravenous injection to treat toxic levels of methotrexate due to kidney failure

Ivacaftor: A new emerging treatment option in the management of cystic fibrosis

Ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, has been approved by FDA for treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation in the CFTR gene. This agent offers a novel approach to the treatment of cystic fibrosis, as it is the only marketed drug that targets the underlying cause of this lethal condition, instead of the downstream disease processes that occur as a result of lacking or defective CFTR.